JP2015534982A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015534982A5 JP2015534982A5 JP2015538060A JP2015538060A JP2015534982A5 JP 2015534982 A5 JP2015534982 A5 JP 2015534982A5 JP 2015538060 A JP2015538060 A JP 2015538060A JP 2015538060 A JP2015538060 A JP 2015538060A JP 2015534982 A5 JP2015534982 A5 JP 2015534982A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- hiv
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261715642P | 2012-10-18 | 2012-10-18 | |
| US61/715,642 | 2012-10-18 | ||
| PCT/US2013/065696 WO2014063059A1 (en) | 2012-10-18 | 2013-10-18 | Broadly-neutralizing anti-hiv antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018243618A Division JP6732872B2 (ja) | 2012-10-18 | 2018-12-26 | 広域中和抗ｈｉｖ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015534982A JP2015534982A (ja) | 2015-12-07 |
| JP2015534982A5 true JP2015534982A5 (https=) | 2016-08-25 |
| JP6461804B2 JP6461804B2 (ja) | 2019-01-30 |
Family
ID=50488789
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015538060A Active JP6461804B2 (ja) | 2012-10-18 | 2013-10-18 | 広域中和抗ｈｉｖ抗体 |
| JP2018243618A Active JP6732872B2 (ja) | 2012-10-18 | 2018-12-26 | 広域中和抗ｈｉｖ抗体 |
| JP2020117726A Active JP7076722B2 (ja) | 2012-10-18 | 2020-07-08 | 広域中和抗ｈｉｖ抗体 |
| JP2022075767A Active JP7376898B2 (ja) | 2012-10-18 | 2022-05-02 | 広域中和抗ｈｉｖ抗体 |
| JP2023180055A Active JP7681278B2 (ja) | 2012-10-18 | 2023-10-19 | 広域中和抗ｈｉｖ抗体 |
| JP2025075098A Pending JP2025118727A (ja) | 2012-10-18 | 2025-04-30 | 広域中和抗ｈｉｖ抗体 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018243618A Active JP6732872B2 (ja) | 2012-10-18 | 2018-12-26 | 広域中和抗ｈｉｖ抗体 |
| JP2020117726A Active JP7076722B2 (ja) | 2012-10-18 | 2020-07-08 | 広域中和抗ｈｉｖ抗体 |
| JP2022075767A Active JP7376898B2 (ja) | 2012-10-18 | 2022-05-02 | 広域中和抗ｈｉｖ抗体 |
| JP2023180055A Active JP7681278B2 (ja) | 2012-10-18 | 2023-10-19 | 広域中和抗ｈｉｖ抗体 |
| JP2025075098A Pending JP2025118727A (ja) | 2012-10-18 | 2025-04-30 | 広域中和抗ｈｉｖ抗体 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US10047146B2 (https=) |
| EP (2) | EP2908912B1 (https=) |
| JP (6) | JP6461804B2 (https=) |
| CN (3) | CN112920269B (https=) |
| AU (4) | AU2013331049B2 (https=) |
| BR (1) | BR112015008635B1 (https=) |
| CA (2) | CA3236192A1 (https=) |
| CY (1) | CY1124405T1 (https=) |
| DK (1) | DK2908912T3 (https=) |
| EA (2) | EA035012B1 (https=) |
| ES (1) | ES2822135T3 (https=) |
| HR (1) | HRP20201505T1 (https=) |
| HU (1) | HUE051577T2 (https=) |
| IL (5) | IL301018B2 (https=) |
| LT (1) | LT2908912T (https=) |
| MX (2) | MX376969B (https=) |
| PL (1) | PL2908912T3 (https=) |
| PT (1) | PT2908912T (https=) |
| SI (1) | SI2908912T1 (https=) |
| WO (1) | WO2014063059A1 (https=) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2467108T3 (es) | 2008-12-09 | 2014-06-11 | Gilead Sciences, Inc. | Moduladores de receptores tipo toll |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| EA032929B1 (ru) | 2011-05-17 | 2019-08-30 | Дзе Рокфеллер Юниверсити | Нейтрализующее вирус иммунодефицита человека антитело и способы его применения |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| LT2908912T (lt) * | 2012-10-18 | 2020-09-25 | The Rockefeller University | Plačiai neutralizuojantys anti-živ antikūnai |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US20160002319A1 (en) * | 2013-02-28 | 2016-01-07 | Therabioli, Inc. | HIV Antigens and Antibodies |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| US10093720B2 (en) * | 2014-06-11 | 2018-10-09 | International Aids Vaccine Initiative | Broadly neutralizing antibody and uses thereof |
| PT3166607T (pt) * | 2014-07-11 | 2022-12-07 | Gilead Sciences Inc | Moduladores de receptores de tipo toll para o tratamento do vih |
| CA2960436C (en) | 2014-09-16 | 2021-01-05 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
| US20170267784A1 (en) | 2014-10-23 | 2017-09-21 | Singh Molecular Medicine, Llc | Single domain antibodies directed against intracellular antigens |
| WO2016149698A2 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies) |
| AU2016326738B2 (en) | 2015-09-24 | 2023-08-31 | Abvitro Llc | HIV antibody compositions and methods of use |
| TWI746473B (zh) * | 2015-11-02 | 2021-11-21 | 美商辛分子醫藥有限公司 | 針對細胞內抗原之單域抗體 |
| WO2018002902A1 (en) | 2016-07-01 | 2018-01-04 | Glaxosmithkline Intellectual Property (No.2) Limited | Antibody-drug conjugates and therapeutic methods using the same |
| US11149082B2 (en) | 2016-10-17 | 2021-10-19 | University Of Maryland, College Park | Multispecific antibodies targeting human immunodeficiency virus and methods of using the same |
| CN118562016A (zh) | 2016-10-21 | 2024-08-30 | 艾尔特生物科技公司 | 基于多聚体il-15的分子 |
| MX2019007738A (es) * | 2016-12-27 | 2019-09-05 | Univ Rockefeller | Anticuerpos contra el vih ampliamente neutralizantes y métodos de uso de ellos. |
| SG11202005557TA (en) | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| EP3755713A1 (en) * | 2018-02-21 | 2020-12-30 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 env and their use |
| US11311603B2 (en) | 2018-06-19 | 2022-04-26 | Nantcell, Inc. | HIV treatment compositions and methods |
| HRP20250618T1 (hr) | 2018-07-03 | 2025-07-18 | Gilead Sciences, Inc. | Protutijela koja ciljaju na hiv gp120 i postupci za uporabu |
| EP3830108A4 (en) * | 2018-07-27 | 2022-08-10 | International AIDS Vaccine Initiative | GENETIC ANTIBODIES AGAINST HIV-ENV |
| WO2020056145A1 (en) * | 2018-09-14 | 2020-03-19 | The Rockefeller University | Anti-hiv antibody 10-1074 variants |
| WO2020159941A1 (en) * | 2019-01-28 | 2020-08-06 | Xyphos Biosciences Inc. | Modified non-natural nkg2d ligands that selectively deliver attached heterologous molecules to non-natural nkg2d receptors on car-cells |
| EP3938379A4 (en) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Hiv rna vaccines |
| WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| WO2020206232A1 (en) * | 2019-04-04 | 2020-10-08 | Vanderbilt University | Hiv/hcv cross-reactive antibodies and uses thereof |
| TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| CN114761041A (zh) | 2019-07-16 | 2022-07-15 | 吉利德科学公司 | Hiv疫苗及其制备和使用方法 |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| CN112759651B (zh) * | 2019-11-01 | 2022-09-20 | 北京华夏清医治疗科技有限公司 | 一种包含嵌合抗原受体修饰的t细胞及其应用 |
| EP3831848A1 (en) * | 2019-12-02 | 2021-06-09 | Universität zu Köln | Broadly neutralizing antibodies against hiv |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| EP4153181A1 (en) | 2020-05-21 | 2023-03-29 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| PE20230779A1 (es) | 2020-08-07 | 2023-05-09 | Gilead Sciences Inc | Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico |
| US12195524B2 (en) | 2020-08-25 | 2025-01-14 | Gilead Sciences, Inc. | Multi-specific antigen binding molecules targeting HIV and methods of use |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN116437958A (zh) | 2020-11-11 | 2023-07-14 | 吉利德科学公司 | 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| DK4445900T3 (da) | 2021-12-03 | 2025-08-18 | Gilead Sciences Inc | Terapeutiske forbindelser til hiv-virusinfektion |
| JP7765637B2 (ja) | 2021-12-03 | 2025-11-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症のための治療化合物 |
| CA3241017A1 (en) | 2021-12-17 | 2023-06-22 | Robert Ferris | Combination therapies for hiv infections and uses thereof |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TWI867601B (zh) | 2022-07-01 | 2024-12-21 | 美商基利科學股份有限公司 | 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物 |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
| KR20250051732A (ko) | 2022-08-26 | 2025-04-17 | 길리애드 사이언시즈, 인코포레이티드 | 광범위 중화 항체를 위한 투여 및 일정 요법 |
| EP4598934A1 (en) | 2022-10-04 | 2025-08-13 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| US20240390349A1 (en) | 2023-04-19 | 2024-11-28 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| KR20260018877A (ko) | 2023-05-31 | 2026-02-09 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 치료에 유용한 화합물의 고체 형태 |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| KR20260046169A (ko) | 2023-07-28 | 2026-04-06 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료 및 예방을 위한 레나카파비르 주간 투여 레지먼 |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| WO2025050404A1 (zh) * | 2023-09-08 | 2025-03-13 | 成都维瑾柏鳌生物医药科技有限公司 | 一种药物组合物及其应用 |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025080850A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TW202515549A (zh) | 2023-10-11 | 2025-04-16 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| US20250230163A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025184609A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Antiviral compounds |
| US20260007683A1 (en) | 2024-06-14 | 2026-01-08 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2026076265A1 (en) | 2024-10-03 | 2026-04-09 | Gilead Sciences, Inc. | Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593A (en) | 1849-07-17 | Cutting | ||
| US81A (en) | 1836-11-15 | Erawijjg | ||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5798251A (en) * | 1990-05-29 | 1998-08-25 | Cedars-Sinai Medical Center | Antibody and antibody derivative immunoreagents reactive with a conserved epitope of Human Immunodeficiency Virus Type 1 (HIV-1) gp 120 |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| JPH10511085A (ja) | 1994-12-02 | 1998-10-27 | カイロン コーポレイション | 二重特異性抗体を用いる免疫応答を促進する方法 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| EP1373318A2 (en) | 2001-01-26 | 2004-01-02 | Abgenix, Inc. | Neutralizing human monoclonal antibodies against hiv-1, their production and uses |
| US7566451B2 (en) * | 2002-05-06 | 2009-07-28 | The United States Of America As Represented By The Department Of Health And Human Services | Human immunodeficiency virus-neutralizing human antibodies with improved breadth and potency |
| US7501494B2 (en) * | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| US20050032042A1 (en) * | 2003-04-14 | 2005-02-10 | Soldin Steven J. | Anti-retroviral analysis by mass spectrometry |
| WO2005058963A1 (ja) * | 2003-12-16 | 2005-06-30 | Kumamoto Technology And Industry Foundation | 抗ｈｉｖ抗体 |
| CN1910289B (zh) * | 2004-01-07 | 2012-05-23 | 日立化成研究中心公司 | 用于检测hiv的引物和探针 |
| JP4895727B2 (ja) * | 2006-08-28 | 2012-03-14 | シスメックス株式会社 | 抗ｈｉｖ抗体検出試薬、試薬キット、試薬の製造方法、及び抗ｈｉｖ抗体の検出方法 |
| WO2008140579A2 (en) * | 2006-11-17 | 2008-11-20 | New York University | Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope |
| EP2178560A2 (en) * | 2007-07-23 | 2010-04-28 | Maxygen, Inc. | Chimeric hiv antigens |
| EP2376651A2 (en) * | 2008-12-19 | 2011-10-19 | Abbott Laboratories | Molecular assay for diagnosis of hiv tropism |
| WO2011092593A2 (en) | 2010-01-20 | 2011-08-04 | Institute For Research In Biomedicine | Hiv-1 neutralizing antibodies and uses thereof |
| RU2535034C2 (ru) | 2010-08-06 | 2014-12-10 | Олег Ильич Эпштейн | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида |
| CA3249351A1 (en) * | 2010-08-31 | 2025-07-03 | Theraclone Sciences, Inc. | Neutralizing antibodies against human immunodeficiency viruses (HIV) |
| WO2012074863A2 (en) * | 2010-12-01 | 2012-06-07 | Albert Einstein College Of Medicine Of Yeshiva University | Constructs and methods to identify antibodies that target glycans |
| LT2908912T (lt) * | 2012-10-18 | 2020-09-25 | The Rockefeller University | Plačiai neutralizuojantys anti-živ antikūnai |
-
2013
- 2013-10-18 LT LTEP13847347.5T patent/LT2908912T/lt unknown
- 2013-10-18 CA CA3236192A patent/CA3236192A1/en active Pending
- 2013-10-18 US US14/436,608 patent/US10047146B2/en active Active
- 2013-10-18 CN CN202110092787.9A patent/CN112920269B/zh active Active
- 2013-10-18 IL IL301018A patent/IL301018B2/en unknown
- 2013-10-18 DK DK13847347.5T patent/DK2908912T3/da active
- 2013-10-18 CN CN202410516500.4A patent/CN118955699A/zh active Pending
- 2013-10-18 EP EP13847347.5A patent/EP2908912B1/en active Active
- 2013-10-18 BR BR112015008635-7A patent/BR112015008635B1/pt active IP Right Grant
- 2013-10-18 CN CN201380064622.4A patent/CN104918658B/zh active Active
- 2013-10-18 MX MX2015004924A patent/MX376969B/es active IP Right Grant
- 2013-10-18 EP EP20182718.5A patent/EP3783018A1/en active Pending
- 2013-10-18 EA EA201590741A patent/EA035012B1/ru unknown
- 2013-10-18 WO PCT/US2013/065696 patent/WO2014063059A1/en not_active Ceased
- 2013-10-18 CA CA2888659A patent/CA2888659C/en active Active
- 2013-10-18 PL PL13847347T patent/PL2908912T3/pl unknown
- 2013-10-18 EA EA201992107A patent/EA201992107A1/ru unknown
- 2013-10-18 SI SI201331809T patent/SI2908912T1/sl unknown
- 2013-10-18 AU AU2013331049A patent/AU2013331049B2/en active Active
- 2013-10-18 PT PT138473475T patent/PT2908912T/pt unknown
- 2013-10-18 HU HUE13847347A patent/HUE051577T2/hu unknown
- 2013-10-18 ES ES13847347T patent/ES2822135T3/es active Active
- 2013-10-18 JP JP2015538060A patent/JP6461804B2/ja active Active
- 2013-10-18 IL IL285049A patent/IL285049B/en unknown
- 2013-10-18 HR HRP20201505TT patent/HRP20201505T1/hr unknown
-
2015
- 2015-04-16 MX MX2020011669A patent/MX2020011669A/es unknown
- 2015-04-16 IL IL238320A patent/IL238320B/en unknown
-
2018
- 2018-06-12 US US16/006,420 patent/US10392433B2/en active Active
- 2018-12-26 JP JP2018243618A patent/JP6732872B2/ja active Active
-
2019
- 2019-02-14 AU AU2019201039A patent/AU2019201039B2/en active Active
- 2019-07-10 US US16/507,867 patent/US11142564B2/en active Active
-
2020
- 2020-07-08 JP JP2020117726A patent/JP7076722B2/ja active Active
- 2020-09-28 AU AU2020244391A patent/AU2020244391B2/en active Active
- 2020-10-21 CY CY20201100995T patent/CY1124405T1/el unknown
-
2021
- 2021-09-09 US US17/470,184 patent/US11649276B2/en active Active
-
2022
- 2022-05-02 JP JP2022075767A patent/JP7376898B2/ja active Active
- 2022-05-25 IL IL293362A patent/IL293362B2/en unknown
-
2023
- 2023-03-29 AU AU2023201926A patent/AU2023201926B2/en not_active Expired - Fee Related
- 2023-04-07 US US18/297,301 patent/US12338277B2/en active Active
- 2023-10-19 JP JP2023180055A patent/JP7681278B2/ja active Active
-
2025
- 2025-04-30 JP JP2025075098A patent/JP2025118727A/ja active Pending
- 2025-05-09 US US19/203,424 patent/US20250320280A1/en active Pending
- 2025-09-15 IL IL323371A patent/IL323371A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015534982A5 (https=) | ||
| RU2016129274A (ru) | Канинизированные мышиные антитела к человеческому pd-1 | |
| JP2019536806A5 (https=) | ||
| JP2011528902A5 (https=) | ||
| JP2012504955A5 (https=) | ||
| JP2014512809A5 (https=) | ||
| RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| JP2018535650A5 (https=) | ||
| JP2010516229A5 (https=) | ||
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| JP2018521638A5 (https=) | ||
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| HRP20231196T1 (hr) | Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba | |
| JP2014511179A5 (https=) | ||
| JP2020508303A5 (https=) | ||
| JP2025131696A5 (https=) | ||
| HRP20201345T1 (hr) | Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba | |
| JP2018035138A5 (https=) | ||
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| JP2018527952A5 (https=) | ||
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| JP2015503909A5 (https=) | ||
| RU2010120879A (ru) | Антитела против g-белка распираторно-синцитиального вируса (rsv) | |
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2021500916A5 (https=) |